EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 51 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $146,926 | -29.3% | 208,701 | -9.9% | 0.00% | -50.0% |
| Q1 2023 | $207,813 | -25.2% | 231,701 | -1.7% | 0.00% | 0.0% |
| Q4 2022 | $278,000 | -85.4% | 235,701 | -6.7% | 0.00% | -88.2% |
| Q3 2022 | $1,902,000 | +34.2% | 252,601 | +12.3% | 0.02% | +41.7% |
| Q2 2022 | $1,417,000 | -25.7% | 224,901 | -2.0% | 0.01% | -7.7% |
| Q1 2022 | $1,906,000 | +55.6% | 229,601 | -2.8% | 0.01% | +62.5% |
| Q4 2021 | $1,225,000 | -51.4% | 236,101 | -37.5% | 0.01% | -55.6% |
| Q3 2021 | $2,522,000 | +7.3% | 377,500 | +36.9% | 0.02% | 0.0% |
| Q2 2021 | $2,350,000 | -6.0% | 275,800 | -2.4% | 0.02% | -21.7% |
| Q1 2021 | $2,500,000 | -27.2% | 282,500 | +1.1% | 0.02% | -32.4% |
| Q4 2020 | $3,435,000 | +82.6% | 279,500 | +20.9% | 0.03% | +61.9% |
| Q3 2020 | $1,881,000 | -19.5% | 231,100 | -5.1% | 0.02% | -25.0% |
| Q2 2020 | $2,338,000 | +38.3% | 243,550 | -2.0% | 0.03% | +16.7% |
| Q1 2020 | $1,690,000 | -55.4% | 248,550 | -2.3% | 0.02% | -41.5% |
| Q4 2019 | $3,789,000 | – | 254,300 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| P.A.W. CAPITAL CORP | 540,000 | $4,482,000 | 4.68% |
| Knoll Capital Management, LLC | 694,232 | $5,762,000 | 3.62% |
| Telemetry Investments, L.L.C. | 213,000 | $1,768,000 | 2.79% |
| ACT CAPITAL MANAGEMENT, LLC | 250,000 | $2,075,000 | 2.20% |
| VR Adviser, LLC | 1,469,767 | $12,199,000 | 1.98% |
| INTERWEST VENTURE MANAGEMENT CO | 560,990 | $4,656,000 | 1.78% |
| 683 Capital Management, LLC | 3,375,000 | $28,013,000 | 1.50% |
| Trellus Management Company, LLC | 300,000 | $2,490,000 | 1.45% |
| Altium Capital Management LP | 440,000 | $3,652,000 | 1.22% |
| CAXTON CORP | 116,884 | $970,000 | 1.21% |